Global Ganja Report

Cannabis has become a global industry, but obviously it is still limited by legal restrictions—and the fact that these increasingly vary from country to country further complicates things. Where is commercial cannabis going and where is it coming from? And how is this likely to change as the international atmosphere further liberalizes?

An international network of non-governmental organizations has submitted a "shadow report" to the United Nations, calling the war on drugs a "spectacular failure"—and calling on the world's governments to reconsider it. The report takes heart from the growing official tolerance of cannabis in several countries around the world, but warns of escalating and horrific repression in the name of drug enforcement in several others. Will the UN take heed when it revisits the question of drug policy in 2019?

Justin Cooper is co-founder and CEO of British Columbia-based Green Planet, which supplies equipment to all of Canada's Licensed Producers of cannabis as well as producing its own line of fertilizers. He speaks with Cannabis Now about the fast-growing legal industry in his country, and what it means for the world.

As the UN General Assembly met in New York, President Trump issued a "Global Call" to renew the war on drugs—to the dismay of activists and dissenting nations. But the UN itself has a contradictory cannabis policy—with some agencies recognizing its efficacy as medicine and others backing the prohibitionist doctrine of the Single Convention treaty.

A verdict against glyphosate producer Monsanto in a case brought by a cancer sufferer has brought world attention to the dangers of pesticides and herbicides. This is a question with implications already felt in the cannabis industry—both legal and illegal.

Having just undertaken a "critical study" of CBD, the non-psychoactive cannabinoid held to have multifarious medicinal applications, the World Health Organization is now opening such a study on THC. Stigmatized due to its psychoactive properties and currently in the shadow of the suddenly sexy CBD, tetrahydrocannabinol shows its own potential for application by the medical industry.

The bureaucracy overseeing California's cannabis industry is moving fast to facilitate insurance coverage for businesses—a question very pressing as wildfires rage through the Emerald Triangle.

California health authorities dealt a blow to the burgeoning CBD business by banning preparations of the cannabinoid derived from industrial hemp rather than psychoactive cannabis. The diktat adds to the legal confusion around CBD, and highlights the need for greater clarity from the competent authorities at both the state and federal level.